Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMuhammad Shaheer MannanINIqra NadeemHRHafsa Arshad Azam Raja

Discussion

Loading...

Member takes

Overview

Meta-analysis shows blinatumomab enhances survival and reduces disease recurrence in pediatric B-ALL, suggesting chemotherapy benefits.

Key Points

  • Blinatumomab improved disease-free survival significantly, reducing recurrence by about 37%.
  • Analysis of four randomized controlled trials included 2,011 pediatric patients with B-ALL, comparing blinatumomab and chemotherapy.
  • Confidence intervals indicated substantial survival advantages, yet MRD clearance showed no significant improvement.
  • High heterogeneity in adverse effects underscores the need for standardized toxicity assessments in pediatric populations.

Cite This Study

Mannan et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4e5https://doi.org/10.1182/blood-2025-6867
View Full Paper
Ask AI
Bookmark
Share